Clinical Trial Update: Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing the appropriate dose of a new gadolinium-based contrast agent for adults undergoing MRI for known or suspected brain or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Pathology

Drugs mentioned

• Bayer gadolinium-based contrast agent (GBCA) - unnamed in summary

Snippet

Sponsor: Bayer | Conditions: Central Nervous System Pathology | Phase 2 | Status: COMPLETED | Results posted: 2023-11-15